Portfolio at a glance
Securities as at June 30, 2022
|
Company |
|
Number of securities |
|
Change since 31.12.2021 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
9 541 028 |
|
(691 945) |
|
USD |
|
37.02 |
|
337.3 |
|
11.8% |
|
13.4% |
|
6.7% |
|
Argenx SE |
|
902 503 |
|
(68 035) |
|
USD |
|
378.88 |
|
326.6 |
|
11.5% |
|
13.0% |
|
1.7% |
|
Neurocrine Biosciences |
|
2 798 437 |
|
(216 963) |
|
USD |
|
97.48 |
|
260.5 |
|
9.1% |
|
10.3% |
|
2.9% |
|
Vertex Pharmaceuticals |
|
950 523 |
|
(79 477) |
|
USD |
|
281.79 |
|
255.8 |
|
9.0% |
|
10.2% |
|
0.4% |
|
Moderna |
|
1 531 951 |
|
(131 398) |
|
USD |
|
142.85 |
|
209.0 |
|
7.3% |
|
8.3% |
|
0.4% |
|
Incyte |
|
2 691 077 |
|
(205 923) |
|
USD |
|
75.97 |
|
195.3 |
|
6.8% |
|
7.8% |
|
1.2% |
|
Intra-Cellular Therapies |
|
3 291 479 |
|
(246 940) |
|
USD |
|
57.08 |
|
179.4 |
|
6.3% |
|
7.1% |
|
3.5% |
|
Alnylam Pharmaceuticals |
|
1 028 929 |
|
(81 071) |
|
USD |
|
145.85 |
|
143.3 |
|
5.0% |
|
5.7% |
|
0.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sage Therapeutics |
|
2 950 278 |
|
(219 826) |
|
USD |
|
32.30 |
|
91.0 |
|
3.2% |
|
3.6% |
|
5.0% |
|
Radius Health |
|
8 733 538 |
|
1 027 824 |
|
USD |
|
10.37 |
|
86.5 |
|
3.0% |
|
3.4% |
|
18.3% |
|
Agios Pharmaceuticals |
|
4 030 792 |
|
(281 500) |
|
USD |
|
22.17 |
|
85.4 |
|
3.0% |
|
3.4% |
|
7.4% |
|
Arvinas |
|
2 065 026 |
|
(111 877) |
|
USD |
|
42.09 |
|
83.0 |
|
2.9% |
|
3.3% |
|
3.9% |
|
Fate Therapeutics |
|
3 458 536 |
|
(242 800) |
|
USD |
|
24.78 |
|
81.9 |
|
2.9% |
|
3.3% |
|
3.6% |
|
Myovant Sciences |
|
5 872 639 |
|
(249 400) |
|
USD |
|
12.43 |
|
69.7 |
|
2.4% |
|
2.8% |
|
6.2% |
|
Relay Therapeutics |
|
3 977 762 |
|
(108 200) |
|
USD |
|
16.75 |
|
63.6 |
|
2.2% |
|
2.5% |
|
3.7% |
|
Revolution Medicines |
|
3 302 562 |
|
(118 900) |
|
USD |
|
19.49 |
|
61.5 |
|
2.2% |
|
2.4% |
|
4.4% |
|
Exelixis |
|
2 654 500 |
|
(180 500) |
|
USD |
|
20.82 |
|
52.8 |
|
1.9% |
|
2.1% |
|
0.8% |
|
Crispr Therapeutics |
|
888 605 |
|
(60 979) |
|
USD |
|
60.77 |
|
51.6 |
|
1.8% |
|
2.0% |
|
1.1% |
|
Esperion Therapeutics |
|
4 194 064 |
|
(283 900) |
|
USD |
|
6.36 |
|
25.5 |
|
0.9% |
|
1.0% |
|
6.7% |
|
Celldex Therapeutics |
|
925 000 |
|
925 000 |
|
USD |
|
26.96 |
|
23.8 |
|
0.8% |
|
0.9% |
|
2.0% |
|
Kezar Life Sciences |
|
3 000 000 |
|
(1 918 148) |
|
USD |
|
8.27 |
|
23.7 |
|
0.8% |
|
0.9% |
|
5.0% |
|
Generation Bio Co. |
|
3 608 280 |
|
(244 900) |
|
USD |
|
6.56 |
|
22.6 |
|
0.8% |
|
0.9% |
|
6.3% |
|
Beam Therapeutics |
|
568 121 |
|
(38 700) |
|
USD |
|
38.71 |
|
21.0 |
|
0.7% |
|
0.8% |
|
0.8% |
|
Macrogenics |
|
7 275 564 |
|
– |
|
USD |
|
2.95 |
|
20.5 |
|
0.7% |
|
0.8% |
|
11.9% |
|
Mersana Therapeutics |
|
3 866 200 |
|
(268 800) |
|
USD |
|
4.62 |
|
17.1 |
|
0.6% |
|
0.7% |
|
4.0% |
|
Essa Pharma |
|
4 990 714 |
|
(25 100) |
|
USD |
|
3.15 |
|
15.0 |
|
0.5% |
|
0.6% |
|
11.3% |
|
Wave Life Sciences |
|
4 494 458 |
|
(108 400) |
|
USD |
|
3.25 |
|
14.0 |
|
0.5% |
|
0.6% |
|
5.2% |
|
Scholar Rock Holding |
|
2 132 725 |
|
(142 400) |
|
USD |
|
5.49 |
|
11.2 |
|
0.4% |
|
0.4% |
|
4.1% |
|
Black Diamond Therapeutics |
|
4 694 113 |
|
1 254 113 |
|
USD |
|
2.46 |
|
11.0 |
|
0.4% |
|
0.4% |
|
12.9% |
|
Molecular Templates |
|
11 192 003 |
|
400 000 |
|
USD |
|
0.91 |
|
9.7 |
|
0.3% |
|
0.4% |
|
19.9% |
|
Homology Medicines |
|
1 622 522 |
|
(114 600) |
|
USD |
|
1.97 |
|
3.1 |
|
0.1% |
|
0.1% |
|
2.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
2 852.4 |
|
100.0% |
|
113.2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
1.9 |
|
|
|
0.1% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(334.5) |
|
|
|
(13.3%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
2 519.8 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate as at 30.06.2022: USD/CHF: 0.9551